Maher E R, Yates J R
Br J Cancer. 1991 Feb;63(2):176-9. doi: 10.1038/bjc.1991.43.
Renal cell carcinoma (RCC) accounts for 2% of all human cancer, but familial cases are infrequent. Riches (1963) and Griffin et al. (1984) in a population-based case-control study found a family history of renal cell carcinoma in 2.4% of affected patients compared to 1.4% of controls. Nevertheless the importance of inherited tumours in clinical practice and medical research is disproportionate to their frequency. In clinical practice recognition of familial RCC can provide opportunities to prevent morbidity and mortality by appropriate screening. In medical research recent advances in molecular genetics offer the prospect of isolating the genes involved in the pathogenesis of familial RCC and of the more common sporadic cases. In this article we review the clinical and molecular genetics of inherited renal cell carcinoma (adenocarcinoma or hypernephroma).
肾细胞癌(RCC)占人类所有癌症的2%,但家族性病例并不常见。里奇特斯(1963年)以及格里芬等人(1984年)在一项基于人群的病例对照研究中发现,2.4%的患病人有肾细胞癌家族史,而对照组这一比例为1.4%。然而,遗传性肿瘤在临床实践和医学研究中的重要性与其发生频率并不相称。在临床实践中,认识到家族性肾细胞癌可为通过适当筛查预防发病和死亡提供机会。在医学研究中,分子遗传学的最新进展为分离出与家族性肾细胞癌以及更常见的散发性病例发病机制相关的基因带来了希望。在本文中,我们综述遗传性肾细胞癌(腺癌或肾上腺样瘤)的临床和分子遗传学。